Method for detection of traumatic brain injury
AssigneeBioscreening & Diagnostics LLC
InventorRay Bahado-Singh
Life of this patent
Estimating the term…
Abstract
The present disclosure describes significant methylation changes in multiple genes and multiple metabolites in body fluid in response to TBI. Gene pathways affected included several known to be involved in neurological and brain function. A large number of good to excellent biomarkers for the detection of TBI was identified. The combination of epigenomic, clinical and metabolomic markers in different combinations overall were highly accurate for the detection of pediatric concussion using Artificial Intelligence-based techniques.
Claims18
A method for diagnosing and treating traumatic brain injury (TBI), wherein the method comprises
- assaying a biological sample from a patient in need of TBI diagnosis comprising nucleic acids to determine a frequency or percentage methylation of cytosine at two or more loci throughout genome;
- comparing the cytosine methylation level of the sample to cytosine methylation level of a control sample thereby diagnosing TBI in the patient, wherein the control sample is a corresponding biological sample from a healthy subject wherein difference in cytosine methylation level between the biological sample and control sample at two or more loci is greater than 2%, and wherein the two or more loci comprise two or more of the following loci:
- cg06393885, cg20569893, cg00611535, and/or cg16882751;
- and
- treating the patient, wherein treating the patient comprises cognitive and physical rest and aerobic treatment, post traumatic headache management and treatment, cognitive impairment treatment, vestibulo-oculomotor dysfunction treatment, or sleep deprivation treatment.
Dependencies are inferred from the claim text.